To assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem
cells (hMSCs) manufactured by Stemedica versus placebo administered intravenously to subjects
with mild to moderate dementia due to Alzheimer’s disease.
To assess the preliminary efficacy of hMSCs versus placebo in subjects with
Alzheimer’s-related dementia, as evidenced by neurologic, functional, and psychiatric
1. Males or females between 55-80 years of age.
2. Diagnosed with mild to moderate dementia for at least 3 months prior to enrollment,
based on the National Institute of Neurological and Communicative
3. Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association
(NINDS-ADRDA) Alzheimer’s criteria.
4. MMSE between 12-24 (inclusive) at time of enrollment.
5. Amyloid-positive florbetapir PET scan.
1. Prior treatment with stem cells.
2. History of intracranial, subdural, or subarachnoid hemorrhage.
3. Subjects with baseline brain MRI showing more than four (4) cerebral microhemorrhages
(regardless of their anatomical location or diagnostic characterization as “possible”
or “definite”), and/or one (1) or more areas of superficial siderosis, and/or evidence
of a prior macrohemorrhage. MRI must include fluid-attenuation inversion recovery
(FLAIR) and T2*-weighted gradient-recalled-echo (GRE) sequences.
4. History of cancer within the past 5 years, with the exception of localized basal or
squamous cell carcinoma.
5. History of seizure disorder.
6. Diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and
7. History of cerebral neoplasm.
8. Myocardial infarction within six months of enrollment.
- John Wayne Cancer Institute @ Providence St. John’s Health Center, Santa Monica, California, United States, 90404